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Abstract
Background: Chronic hepatitis B infection is a significant cause of morbidity and mortality worldwide; low- and
middle-income countries (LMICs) are disproportionately affected. Economic evaluations are a useful decision tool to
assess costs versus benefits of hepatitis B virus (HBV) screening. No published study reviewing economic evaluations
of HBV screening in LMICs has been undertaken to date.
Methods: The following databases were searched from inception to 21 April 2017: MEDLINE, PubMed, EMBASE,
CINAHL Plus, the Cochrane Library, Global Health and the Cost-effectiveness Analysis Registry. English-language
studies were included if they assessed the costs against the benefits of HBV screening in LMICs. PROSPERO
registration: CRD42015024391, 20 July 2015.
Results: Nine studies fulfilled the eligibility criteria. One study from Thailand indicated that adding hepatitis B
immunoglobulin (HBIG) to HBV vaccination for newborns following screening of pregnant women might be
cost-effective for some LMICs, though inadequate total funding and health infrastructure were likely to limit
feasibility. A similar study from China indicated a benefit to cost ratio of 2.7 from selective HBIG administration to
newborns, if benefits were considered from a societal perspective. Of the two studies assessing screening amongst
the general adult population, a single cost-benefit analysis from China found a benefit to cost ratio (BCR) of 1.73 with
vaccination guided by HBV screening of adults aged 21–39, compared to 1.42 with vaccination with no screening,
both from a societal perspective. Community-based screening of adults in The Gambia with linkage to treatment
yielded an incremental cost per disability-adjusted life year averted of $566 (in 2017 USD), less than two-times gross
domestic product per capita for that country.
Conclusions: Screening with ‘catch-up’ vaccination for younger adults yielded benefits above costs, and screening
linked with treatment has shown cost-effectiveness that may be affordable for some LMICs. However, interpretation
needs to account for total cost implications and further research in LMICs is warranted as there were only nine
included studies and evidence from high-income countries is not always directly applicable.
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Background
The hepatitis B virus (HBV) can lead to acute and/or
chronic hepatitis B infection (CHB). HBV can be trans-
mitted vertically, horizontally (e.g. child-to-child), sexu-
ally or parenterally [1]. Hepatitis B surface antigen
(HBsAg)-positive individuals who are also positive for
the hepatitis B e antigen (HBeAg) are at an especially
high risk of transmitting HBV to others [2]. For women
who are HBeAg-positive, administering hepatitis B im-
munoglobulin (HBIG) to newborns, as an addition to
HBV vaccination can further prevent the risk of vertical
transmission [3]. The vast majority of HBV-related deaths
are due to longer-term complications from CHB, defined
as HBsAg persistence for more than six months. These
include cirrhosis and hepatocellular carcinoma (HCC) [2].
An estimated 686,000 people died due to HBV infection
in 2013 [4]. The highest prevalence of HBsAg persistence
is in sub-Saharan Africa, East Asia, the Amazon and
southern part of eastern and central Europe [5]. The com-
plications of CHB are costly to manage, the authors of a
2009 study from China [6] report annual per-person costs
of between $1636 and $6054. Although HBV vaccination
has decreased incidence, prevalence of HBV in the low
and middle-income countries (LMICs) remains high due
to insufficient coverage rates of vaccination and limita-
tions in other preventive measures [7].
Screening for HBV, usually via HBsAg (see Table 1),
can help identify individuals at risk of developing
complications from HBV infection and/or of transmit-
ting it to others. This is important, as people infected
with HBV may well be unaware [8]. With advances in
point-of-care testing, screening for HBV is convenient
and inexpensive [9]. The cost of treatment has tradi-
tionally been a barrier restricting follow-up treatment,
though this cost has decreased in recent years [10, 11].
International guidelines recommend ‘high-risk’ groups
screening (e.g. household and/or sexual contacts of
persons with CHB) [3, 12]. However, the feasibility of
screening in many LMICs is limited, including of preg-
nant women to reduce vertical transmission [13],
amongst whom screening uptake in LMICs is low [14].
Given a high prevalence of HBV in LMICs, relative to
high-income countries (HICs), screening of the general
population rather than targeting specific subpopula-
tions may be a more effective strategy to reduce the
HBV burden. The World Health Organization (WHO)
conditionally recommends general population testing
for settings with HbsAg seroprevalence of ≥2%, and
strongly recommends screening of pregnant women in
settings with the same seroprevalence ([12], p. xxviii).
The cost-effectiveness of screening is an important
consideration, especially in resource-constrained set-
tings [15]. An understanding of the economic evidence
available to guide HBV screening policy in LMICs is
therefore important.
To date, there appears to be no published review
assessing economic evaluations of HBV screening in
LMICs. Because there are differences in HBV epi-
demiology and in the application of cost-effectiveness
thresholds in LMICs, and because HBV is dispropor-
tionately concentrated in these countries, a critical
review of studies assessing HBV screening cost-
effectiveness in LMICS is indicated to guide policy
and research in this area. This study aimed to: i) sys-
tematically review the available economic evidence on
HBV screening of the general population/specific sub-
populations in LMICs and provide a narrative synthe-
sis of progress so far, and; (ii) analyse the strengths
and limitations of existing economic evaluations, to
provide research and policy recommendations for
future research.
Methods
Protocol registration and reporting structure
A protocol for this review was prospectively registered on
20 July 2015 (PROSPERO Registration: CRD42015024391
[16]. This report was based on the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
statement [17].
Eligibility criteria
A priori inclusion criteria for this review were cate-
gorised according to the population, intervention, com-
parator, outcome and setting (PICOS) format.
Table 1 Interpretation of markers used in hepatitis B
screening [2, 53]
Marker (abbreviation) Description
Hepatitis B surface antigen
(HBsAg)
marker of acute or chronic
hepatitis B infection
Hepatitis B surface antibody
(anti-HBs)
a high level indicates previous
infection or response to
vaccination and current
immunity (generally ≥10 IU/L
considered ‘protected’)
Hepatitis B e antigen (HBeAg) presence indicates high
infectivity
Total hepatitis B core antibody
(anti-HBc)
indicates resolved infection
if positive for this and
hepatitis B surface antibody,
but negative for HBsAg;
will be positive along with
HBsAg in acute or chronic
hepatitis B infection; if positive
but negative for HBsAg and
hepatitis B surface antibody,
usually indicates distant
resolved hepatitis B infection
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Inclusion criteria
Population: the general population (including blood do-
nors, but not if screening is not linked to follow-up
treatment), or any specified subpopulation.
Intervention: screening for HBV.
Comparator: no screening (e.g. universal vaccination)
or alternate screening scenarios.
Outcome: measuring and reporting quantitative costs
and benefits.
Setting: studies conducted in/using data from LMICs
as defined for the 2016 fiscal year by the World Bank
and/or using data from these countries [18].
Exclusion criteria
1. Studies not considered ‘full economic evaluations’
(i.e. considering either costs or consequences of
HBV screening, but not both in relation to one
another). Studies assessing the HBV prevalence at
which screening becomes less expensive than
universal HBV vaccination (i.e. cost-minimisation
analyses), systematic reviews and conference
abstracts were also excluded.
2. Studies with no full-text version available in English.
Information sources
Two systematic reviews on HBV screening economic
evaluations had already been conducted at the time this
project was commenced, though the eligibility criteria
meant that only studies from HICs were included [19, 20].
The following databases were searched from inception to
2 August 2015: MEDLINE (via OVID), PubMed, EMBASE
(via OVID), the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) Plus (via EBSCO), the
Cochrane Library, EconLit (via OVID), Global Health (via
OVID), Open Grey and the Cost-effectiveness Analysis
(CEA) Registry [21]. An update of the search, exclud-
ing EconLit and Open Grey, was conducted on 21
April 2017.
Search strategies were based around the National
Health System Economic Evaluation Database (NHS
EED) filters available for MEDLINE, PubMed, EMBASE
and CINAHL [22]. The search for each database roughly
comprised: <terms from NHS EED filter to identify eco-
nomic evaluation, removing date, article type and journal
restrictions> AND< terms to identify studies on HBV in
humans> AND< terms to identify studies on screening>.
Medical Subject Heading and EMTREE (for EMBASE)
terms were used where appropriate, in addition to free
text terms with relevant truncations (e.g. test$), using or
adapting search terms reported by Geue and colleagues
[20]. The search strategies used for each database are
provided in Additional file 1.
Experts at the London School of Hygiene and Trop-
ical Medicine (and elsewhere, as referred) were con-
tacted in June 2015 to identify unpublished work that
may be missed through database searching. Undupli-
cated references were checked by hand for each in-
cluded paper, as were the references for the screening
section of recently published WHO HBV guidelines [3].
The Web of Science database was searched on 14 July
2017 for studies citing included articles.
Study selection
The title and abstract of unduplicated articles were
screened against each eligibility criterion in-turn by one
author (CMW or NTH). Two authors (CMW, LB and/
or NTH) independently screened articles advancing to
full-text review, with disagreements resolved through
discussion. The reason for article rejection was recorded
at both screening stages.
Data collection process and items
The Consolidated Health Economics Evaluation Reporting
Standards (CHEERS) statement was used as a basis for the
data extraction form [23]. Data were grouped into the
areas of: 1) title and abstract; 2) introduction; 3) methods;
4) results; 5) discussion; and 6) other (refer to [23] for spe-
cific data items). Data were extracted in the currency used
in the study and, if necessary, converted to United States
Dollars (USD) using the currency conversion figure pro-
vided in the paper or, if not reported, historical conversion
rates for 30 June of the year of publication [24]. For this
review reported costs were expressed in 2017 USD
(inflated from mid-year using consumer price indices
[25]). Two authors extracted data independently (shared
between CMW, LB and NTH). Disagreements in data
extraction were settled through discussion.
Critical appraisal
The Consensus of Health Economic Criteria (CHEC)
checklist and the quality appraisal tool developed by
Philips and colleagues were used to critically appraise in-
cluded studies [26, 27]. Where relevant, the Drummond
et al. checklist was also consulted [28]. As this review fo-
cused on LMICs, the methodological specifications of
the Gates Reference Case were used to assess the appro-
priateness of study methods [29].
Results
Study selection
Database searching returned 4427 unduplicated records.
Of these, 4320 were removed during title and abstract
screening, leaving 107 articles to undergo full-text re-
view. Nine of these articles fulfilled the eligibility criteria
[30–38]. A further 354 unduplicated articles were identi-
fied via reference and citation checking; none of these
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fulfilled the eligibility criteria. Figure 1 shows the search
strategy results in detail; rejected articles at the full text
review stage are listed in Additional file 2.
Study characteristics
The included studies were published from 1989
through 2016 and used data from Iran [30], India [31],
South Africa [33], the Philippines [34], Thailand [36,
37], China [32, 38] and The Gambia [35]. More recent
studies were conducted and reported with greater
adherence to contemporary economic evaluation
guidelines (see ‘critical appraisal’ section in methods).
Five studies focused on screening strategies for preg-
nant women and the resulting clinical intervention that
would then be appropriate for the infant postpartum
[31–34, 36]. The remaining studies focused on screening
adults [30, 35, 37, 38]. Studies reported variable outcomes.
Summary characteristics and main results for included stud-
ies are provided in Table 2, with the complete data extracted
from each study provided in Additional file 3.
Fig. 1 Flow diagram of study selection
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Study findings
Antenatal screening
Vimolket and Poovorawan [36] analysed the addition of
HBIG to a universal 3-dose HBV vaccination programme
for newborns in Thailand, following HBV screening of
pregnant women. The incremental cost-effectiveness ra-
tio (ICER), expressed as cost per case prevented, was
$211 for universal vaccination relative to the next least
costly option of no vaccination of newborns. This was
much less than the $3067 ICER for screening of HBsAg,
followed by 3 doses of HBV vaccine over six months for
the infant if the mother tests positive, compared to a 2-
stage screening strategy universal HBV vaccination and
HBsAg screening, followed by HBeAg if positive, with
HBIG administered if HBeAg-positive. This in-turn had
an ICER of $646 per case prevented, when compared to
universal vaccination with no screening. These authors
state that a challenge to interpreting their results is that,
“there is no socially acceptable threshold for cost per
case prevented to guide decisions…” [36]. They conclude
that universal vaccination with no screening should con-
tinue with current programme funding levels, though a
policy of HBsAg followed by HBeAg screening if positive,
with HBIG administration if positive for both could be
cost-effective and feasible if funding could be doubled [36].
More recently, Chen and colleagues [32] reported a
cost-benefit analysis comparing HBV vaccination with
HBIG administration for newborns of HBsAg-positive
mothers to either, universal HBV vaccination or no vac-
cination, both with no screening. The ‘base case’ analysis
compared HBV vaccination, with HBIG only for new-
borns of mothers screening positive for HBsAg, with no
vaccination. This yielded a benefit to cost ratio (BCR) of
193, from societal perspective. BCRs for this comparison
were insensitive to prices changes of HBV vaccine or
HBIG. Compared to universal HBV vaccination, screen-
ing mothers with the addition of HBIG for newborns of
HBsAg-positive mothers averted 3500 HBV cases (in a
birth cohort of 16.4 million newborns) and yielded BCRs
of 0.4 (direct costs) and 2.7 (from a societal perspective).
The other three older studies of antenatal screening
[31, 33, 34] primarily assessed HBV screening as a means
of targeting HBV vaccination, versus universal vaccin-
ation. Two of these studies, one each from South Africa
and India, recommended universal HBV vaccination ra-
ther than screening-based vaccine targeting [31, 33],
whilst the third study from the Philippines found screen-
ing most likely to be cost-effective when the cost of
HBV vaccine was very high [34].
Screening of pre-marital couples
The authors of the study from Iran report an economic
analysis comparing strategies screening premarriage
couples of HBV, via HBsAg (strategy 1) plus the core
antibody for negative partners in serodiscordant couples
(strategy 2) [30]. An average cost-effectiveness of $269
per chronic infection averted was reported for strategy 1;
for strategy 2 the value was $263. The authors assessed
the impact of the values they included in their model and
found that uncertainty associated with these could give a
range of $89 – $440 and $88 – $412 for strategy 1 and 2
respectively. The authors modelled the costs of screening
a 25-year old, to a 50-year old developing chronic liver
disease (CLD) secondary to CHB for ten years, discount-
ing costs at 3%. They estimate that above a cost of $3758
for strategy 1 and $3663 for strategy 2 for managing CLD,
screening of premarriage couples is likely to be cost
saving. This study assumed no pre/extra-marital sex.
Screening of people traveling abroad for work
One of the studies from Thailand modelled the costs of
screening people travelling abroad for work for HBsAg prior
to leaving, versus the cost of returning home to Thailand if
HBV infection is detected once they are abroad [37]. The
author estimates cost savings of $81,768 to $396,726 for a
hypothetical cohort of 10,000 workers. This is a brief article,
which does not explain why returning is necessary.
Screening of general adult population
Authors of a recent study from China assessed the effect
of providing 3 doses of HBV vaccination to adults aged
21–39 years, and 40–59 years [38]. They assessed the
costs of vaccination with or without screening to deter-
mine who should be offered ‘catch up vaccination’, versus
the costs averted from reduced HBV-related morbidity
and mortality. The results of this cost-benefit analysis
were given from both a direct costs and a societal costs
perspective. Societal costs included indirect costs of
earning potential work forfeit via HBV-associated mor-
bidity and early mortality. For younger adults aged 21–
39 years, the BCR was 1.19 considering direct costs, and
1.73 from a societal perspective (i.e.). This is compared
to 1.06 and 1.42 respectively for vaccination of this age
group without prior screening. The BCR remained > 1
for sensitivity analysis of model parameters including
vaccine cost. The BCRs were less than 1 for adults aged
40–59 years, indicating the costs of the program would
exceed the expected costs averted. The total costs
exceeded $1.4 billion for each scenario. The authors rec-
ommended that policy makers consider a targeted HBV
vaccination program for younger adults in China.
Authors of a recent study from The Gambia [35] mod-
elled community-based screening of adults at mean age
38 with a rapid HBsAg test, followed by treatment with
tenofovir where indicated. The base model in this ana-
lysis, where HbsAg positive prevalence was 8.8%, gener-
ated ICERs of $566 per disability-adjusted life year
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(DALY) averted, $677 per life year gained and $536 per
quality-adjusted life year gained. In sensitivity analyses,
the drug cost and treatment, cost of screening and pro-
gression of HBsAg-positive, but HBeAg-negative pa-
tients to decompensated cirrhosis had the greatest
potential to increase the ICERs. With a willingness-to-
pay of three-times the gross domestic product of The
Gambia, screening was very likely to be cost-effective,
though with a more conservative World Bank target of
less than $240 per DALY averted, screening was unlikely
to be cost-effective. Authors of this study recommended
integration of screening into existing public health
programs [35].
Critical appraisal of included studies
All but three of the studies assumed 100% compliance
with interventions [32, 35, 38]. The choice of decision
tree modelling limited the ability to formally assess con-
sequences over time for most studies [30, 31, 34, 36, 38].
However, the studies from China and The Gambia
[32, 35, 38] took a lifetime perspective and considered
morbidity and death resulting from CHB. Cost data
primarily consisted of direct costs (e.g. of the screening it-
self). The perspective of the analysis (i.e. who was paying
the costs) was stated clearly for only four of the studies
[30, 35, 36, 38]. In the cases were costs and benefits were
discounted, an appropriate value of 3% was used [29, 30,
32, 35, 38]. Clearly reported sensitivity analyses were per-
formed for five studies [30, 32, 35, 36, 38]. Among studies
for which sensitive analyses were reported, major influen-
tial parameters include costs of screening tests [35, 36],
prevalence of HBV, screening uptake rate, health utility
calculation and discount rate [35].
Discussion
This review demonstrates that there are few economic
evaluations of HBV screening in LMICs. More recent
studies have most relevance to contemporary public
health practice and were generally reported with greater
transparency and consideration of the effect of uncer-
tainty on the results generated. Earlier studies tended to
focus more on vaccination, the cost-effectiveness of
which in LMICs has been reviewed elsewhere [39, 40].
While the cost-effectiveness of HBV screening has been
reviewed for studies conducted in HICs [19, 20], in
LMICs there is relatively less concentration of HBV in
‘high risk’ groups and there are often markedly different
willingness-to-pay thresholds [41].
Three studies included in this review evaluated the
cost-effectiveness of adding HBIG to HBV vaccination
for newborns born to HBsAg +/− HBeAg-positive
mothers [32, 34, 36]. The outcomes reported and ap-
proach taken by the authors of 1989 study [34] limits
the usefulness of their results. The authors of the more
recent study by Vimolket and Poovorawan [36] conclude
that feasibility in resource-constrained settings was lim-
ited by allocated budget and logistical support required
to implement the service [36]. A more recent study from
China, by Chen and colleagues [32] indicated a benefit
above cost from a societal perspective for adding HBIG
to HBV vaccination for newborns of HBsAg-positive
mothers. However, the assessment of uncertainty in this
modelling focused on the comparator with no vaccin-
ation. Given high HBV vaccine coverage in China [42],
further exploration of the comparison with universal
vaccination would have been helpful. Authors of a 2013
study assessed the cost-effectiveness of augmenting HBV
vaccination with HBIG, this time with cost data from
Taiwan, a HIC [43]. These authors model the ICERs of
different HBV screening strategies over four levels of
HBV prevalence 1%, 5%, 15% and 25%. However, each of
the strategies explored by these authors, involving
screening and administering HBIG based on the results,
had incremental costs per infection averted, relative to
universal vaccination without screening, >$1500 (in
2011 USD), likely limiting the cost-effectiveness in many
LMICs.
With the increase in coverage of universal infant HBV
vaccination, the horizontal transmission of HBV has de-
creased, with a reduction in HBsAg prevalence among
children seen in many settings including China [44] and
Cambodia [45]. With ~ 50% likelihood of progression to
CHB if infected as a child, this should lead to gains in
terms of lower CHB amongst vaccinated populations as
they age [46]. However, the WHO estimates the full ef-
fects – via a reduction in HBV-associated mortality – of
universal HBV vaccination of new-borns will not be rea-
lised for 20 to 40 years [3]. Treatment has been found to
markedly reduce the progression of CHB to complica-
tions of cirrhosis and HCC [47]. The screening princi-
ples put forward by Wilson and Jungner [15] highlight
the importance of having an “accepted treatment” and
“agreed policy on whom to treat”. Recently published
WHO guidelines thus strengthen the case for HBV
screening [3, 12]. The authors of the study from China
[38] sought to assess the BCR of ‘catch up’ three-dose
HBV vaccination for young adults who may not have
benefitted from universal infant vaccination, from a soci-
etal perspective. These authors report that screening
prior to vaccination yielded a higher BCR amongst
younger adults (21–39 years). Only one study assessed
community-based screening linked to treatment and
found the cost-effectiveness to be dependent on the
willingness-to-pay threshold applied [35].
Given that DALY averted is used in the WHO’s
CHOICE values [48], future studies should include this
as one of the outcome measures (indicative disability
weights for The Gambia have been published [39]).
Wright et al. BMC Public Health  (2018) 18:373 Page 9 of 12
Considering the ICER in terms of total budget impact is
also important, especially for applying the findings from
these more widespread strategies in the studies from
China and The Gambia [39, 49]. This is because
willingness-to-pay thresholds differ between countries,
and need to be applied with due consideration of con-
text and competing health priorities [41]. More widely,
Nayagam and colleagues [50] have separately modelled
the costs of global elimination of HBV including a wide-
spread testing and treating strategy.
Geue and colleagues [20] have critically assessed cost-
effectiveness modelling studies of HBV screening in Or-
ganisation for Economic Cooperation and Development
member countries and their findings of higher quality
amongst more recent studies is consistent with our
findings. A systematic review by Hahné and colleagues
[19] also included cost-effectiveness studies from HICs.
While these authors’ review focused on implications of
HBV screening economic evaluations for European
countries, some of the findings may have implications
for future research in LMICs. They suggest considering
that the cost-effectiveness of antenatal screening might
be improved if antiviral treatment of the mother is also
considered [19]. This is not a scenario explored by the
antenatal screening studies from LMICs included in our
review. Since database searching, a narrative review of
‘test and treat’ strategies as relevant to LMICs has been
reported by Nayagam and colleagues [51]. Consistent
with our findings, these authors were only able to find
one relevant study conducted in LMICs [35]. Our study
should be read in conjunction with these reviews, espe-
cially given the small number of studies conducted in
LMICs.
Strengths of this study include a comprehensive search
strategy, methodological critical appraisal and prospect-
ive protocol registration. Limitations of the review in-
cluded exclusion of non-English language studies, of
studies screening blood where no linkage to treatment
followed, and that only nine studies fulfilled the eligibility
criteria, meaning that any publication bias may have an
impact on the conclusions drawn from the literature. The
definition of LMICs for the 2016 fiscal year could have
created issues where countries had changed from low-or
middle-, to high-income. However, this was not an issue
during study selection. That we have expressed costs in
2017 USD does not mean costs between studies are dir-
ectly comparable, due to different study methods and pe-
riods. Finally, the different target populations, different
prevalence of HBV infection (for example, between China
[44, 52] and The Gambia [35]) and that the two studies
looking at the general population took different ap-
proaches – one a cost-utility analysis [35], the other a
cost-benefit analysis [38] – limited our ability to aggregate
findings quantitatively across studies.
Conclusions
Further, high quality study of HBV screening cost-
effectiveness in LMICs is warranted, ideally linked with
treatment for those found seropositive, as community-
based screening has the potential to require significant
investment. Current evidence is equivocal regarding the
feasibility of screening of pregnant women linked with
HBIG administration to newborns in LMICs, though the
WHO recommends screening amongst this subpopula-
tion ([12], p. xxviii). At this stage, screening with ‘catch-
up’ vaccination for younger adults has some evidence of
benefit above cost, though from a single study [38],
whilst a study assessing screening people > 30 years, with
follow-up treatment, has yielded ICERs that may be af-
fordable for some LMICs [35].
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